Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||COX-2 inhibition and thrombotic tendency: a need for surveillance|
|Citation:||Medical Journal of Australia, 2001; 175(20 August 2001):214-217|
|Publisher:||Australasian Med Publ Co Ltd|
|Cleland, L G ; James, M J ; Stamp, L K ; Penglis, P S|
|Abstract:||Cyclooxygenase-2 (COX-2) inhibitors belong to a new class of drugs which have anti-inflammatory efficacy similar to that of traditional non-steroidal anti-inflammatory drugs (NSAIDs), but are associated with a reduced incidence of adverse upper gastrointestinal events. Biochemical evidence that COX-2 inhibitors could promote or exacerbate a tendency to thrombosis is supported by recent results from clinical trials and case reports. Two agents in this class, celecoxib and rofecoxib, have been listed on the Pharmaceutical Benefits Scheme (PBS) for very broad indications in chronic arthropathies, suggesting that they will move into widespread community use. It is important to canvass the possibility that use of these agents could be associated with thrombotic events.|
Anti-Inflammatory Agents, Non-Steroidal
Randomized Controlled Trials as Topic
|Appears in Collections:||Aurora harvest|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.